Study subjects undergo leukapheresis followed by lymphodepletion with either fludarabine 30mg/m2 and cyclophosphamide 500mg/m2 for 3 days (Arm 1) or 60 mg/kg cyclophosphamide for 2 days (Arm 2). All subjects will be followed for adverse events, CAR-T-related toxicities, disease response and PRGN-3007 cell expansion and persistence. In addition, the mechanisms of safety and effectiveness of PRGN-3007 cells will be evaluated with correlative assays of specific immune response pathways.

2 years ago

Clinical • P1 data • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • CCND1 (Cyclin D1) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1) • IL15 (Interleukin 15)

PD-1 expression • ROR1 expression • CCND1 overexpression

cyclophosphamide • fludarabine IV • Ovarian cancer CAR-T therapy • PRGN-3005 • PRGN-3007

3years

Preclinical Evaluation of Prgn-3007, a Non-Viral, Multigenic, Autologous ROR1 Ultracar-T® Therapy with Novel Mechanism of Intrinsic PD-1 Blockade for Treatment of Hematological and Solid Cancers (ASH 2021)

Data shown is from 8 mice/group at the start of the study. * p<0.05, ***p<0.001; log rank test.

3 years ago

Preclinical • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)

PD-1 expression • ROR1 expression

PRGN-3005 • PRGN-3007